• Identify and review current approaches to assessing economic impact of NM.
   Accumulate data available between public and private sector inputs
   Redefine the ‘size’ component of NT to Nanomedicine
    o What are their limitations?
       Real market is hidden b/c companies do not specifically identify product or
          pipeline as “nanomedicine product”
       Difficulties in defining downstream components of economic impact
       Defining the intersection of nano- and bio-centric Medicine
    o Are they broadly applicable?
      
    o Are there sufficient data available?
       Depends on where on draws the lines for the definition of ‘nano’ medicine
       Sentiment that there is data available, but it is difficult to categorize b/c
          SME/industry may not consider/want to consider their product as
          ‘nanotechnology’
• What is not currently being captured by metrics that should be?
  o Spillover effects beyond spending input/outputs
  o Proper assignment of regional “economic multipliers”
  o The potential for advanced diagnostics for longer life through earlier detection
  o Recalcitrance of adoption of nanomedicine into standard of care and coverage by
    insuring agencies
  o Bottlenecks to development and implementation
  o The future of the health system
     Changing of pharmaceutical R/D/implementation paradigm
     The “IF” a reimbursement agency will cover a given therapy/diagnostic
• What is a reasonable objective to set for the economic assessment of the impact of NT in each
  sector in 3-5 years?
  o Needs to be done to support further government support of nascent technology
  o Re-categorization of current Tx + Dx on market to define nano-component of the market
     Get government to refine standard industrial code to
  o Develop scenarios on novel treatments, advanced diagnostics, of likely impacts: use as
    predictive econ models
     Life expectancy
     Reduced hospital stay